Efruxifermin
Based on 2 publication(s) in Google Scholar
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis.
For research use only. We do not sell to patients.
- Purity: 98.58%
- CAS No.: 2375240-92-7
- Molecular Weight:91.863 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Efruxifermin
More-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
RT-PCR
-
WB
-
IF
Biological Activity
Human
|
FGFR1 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male and female Sprague Dawley rats[1]
-
Dosage:0, 1, 10, 30, 100 mg/kg
-
Administration:Subcutaneous injection, Once weekly, for 4 or 26 weeks
-
Result:Significantly reduced body weight gain after 4 and 26 weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IGHG1 Fc (Fragment constant)-[FGF21 (fibroblast growth factor 21)]2
-
Loaded Efruxifermin on Protein A Chip, can bind Klotho beta Protein, Human (HEK293, His, HY-P77972) with an affinity constant of 2.21E-08 M as determined in SPR assay.
Chemical Information
-
CAS No. 2375240-92-7
-
Appearance Liquid
-
Molecular Weight 91.863 kDa
-
Color Colorless to light yellow
-
SMILES
[Efruxifermin]
-
Synonyms
AKR-001; AMG-876
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Adv Res
FGF21-FGFR1 signaling protects against cardiac hypertrophy by regulating PINK1-mediated mitophagy pathway. [Abstract]2025 Oct 29:S2090-1232(25)00848-3. PMID: 41173187
Efruxifermin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 29:S2090-1232(25)00848-3. [Abstract]
Efruxifermin (FGF21; 1 mg/kg; subcutaneous injection). Measurement of LVEF in the indicated groups.
Efruxifermin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 29:S2090-1232(25)00848-3. [Abstract]
Efruxifermin (FGF21; 1 mg/kg; subcutaneous injection). Representative image of HE staining.
Efruxifermin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 29:S2090-1232(25)00848-3. [Abstract]
Efruxifermin (FGF21; 1 mg/kg; subcutaneous injection). ANP and BNP mRNA levels in the indicated group.
Efruxifermin purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 29:S2090-1232(25)00848-3. [Abstract]
Efruxifermin (FGF21; 1 mg/kg; subcutaneous injection). ANP and BNP protein levels in the indicated group.
-
Research (Wash D C)
Fibroblast Growth Factor 21 Promotes Vascular Smooth Muscle Cell Contractile Polarization via p38 Mitogen-Activated Protein Kinase-Promoted Serum Response Factor Phosphorylation. [Abstract]2025 Aug 5:8:0815. PMID: 40765997
Efruxifermin purchased from MedChemExpress. Usage Cited in: Research (Wash D C). 2025 Aug 5:8:0815. [Abstract]
Efruxifermin (5 mg/kg; subcutaneous injection). The expression of SMA and OPN in SMA-positive cells in neointimal areas was determined by immunofluorescence staining.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)